Insider Purchase: Immix Biopharma CEO Adds 2,500 Shares (IMMX)

Rhea-AI Filing Summary

Immix Biopharma insider purchase by CEO/Chairman — This Form 4 shows that Ilya M. Rachman, who is identified as a director and as the CEO and Chairman of Immix Biopharma, Inc. (IMMX), purchased 2,500 shares of the company on 09/17/2025 at a volume-weighted average price of $2.02 per share. After the purchase, the filing reports that Mr. Rachman beneficially owned 1,140,937 shares. The filing includes an explanation that the $2.02 VWAP reflects purchases executed at prices ranging from $2.01 to $2.02 and offers to provide transaction-level detail on request. The form is signed by the reporting person on 09/17/2025.

Positive

• Insider purchase disclosed: CEO/Chairman Ilya M. Rachman purchased 2,500 shares on 09/17/2025.
• Increased reported beneficial ownership: Post-transaction beneficial ownership reported as 1,140,937 shares.
• Transparent pricing detail: VWAP disclosed and range ($2.01–$2.02) acknowledged with offer to provide full trade detail on request.
• Timely, signed filing: Form 4 is signed by the reporting person and dated 09/17/2025, indicating compliance with reporting rules.

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchase reported by the CEO/Chairman of 2,500 shares at $2.02, modest in size relative to total holdings but signals direct CEO participation.

The Form 4 documents a small open-market purchase by Ilya M. Rachman on 09/17/2025 for 2,500 common shares at a VWAP of $2.02. The filing reports his total beneficial ownership as 1,140,937 shares after the transaction. No derivative transactions or disposals are reported. The disclosure is routine and complies with Section 16 reporting: it provides the VWAP range and offers to furnish granular trade details upon request. Given the limited transactional size disclosed, the direct market impact is likely minimal; the primary relevance is transparency regarding current insider holdings.

Corporate Governance Expert

TL;DR: Timely Form 4 filing shows compliance and updated insider stake; transaction size appears routine.

The filing identifies the reporting person as both a director and as the CEO and Chairman, and it reports an open-market acquisition of 2,500 shares on 09/17/2025. The document includes a standard explanation of the VWAP and a manual signature dated 09/17/2025, indicating proper execution. From a governance perspective, the disclosure meets Section 16 requirements and updates public records of insider ownership. The filing contains no indications of option exercises, sales, or other compensatory transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Rachman Ilya M

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		P		2,500	A	$2.02(1)	1,140,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Volume-weighted average price of purchases which transactions occurred at purchase prices from $2.01 to $2.02 per share, inclusive. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Ilya Rachman	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Ilya Rachman report on the IMMX Form 4?

The Form 4 reports that Ilya M. Rachman purchased 2,500 shares of Immix Biopharma on 09/17/2025.

At what price were the IMMX shares purchased according to the Form 4?

The reported volume-weighted average price was $2.02 per share, with purchases executed from $2.01 to $2.02.

How many IMMX shares does Ilya Rachman beneficially own after the transaction?

The filing reports a post-transaction beneficial ownership of 1,140,937 shares.

What is Ilya Rachman's role at Immix Biopharma as stated in the filing?

The Form 4 identifies Ilya M. Rachman as a Director and as the CEO and Chairman of Immix Biopharma.

Does the Form 4 show any derivative transactions or sales by the reporting person?

No; the Form 4 lists only a non-derivative purchase of common stock and shows no derivative transactions or dispositions.